Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Benzgalantamine · Zunveyl, ALPHA-1062

Small molecule · Inhibitor of acetylcholinesterase (ACHE) · developed by Alpha Cognition

Approved FDA, Jul 2024

ACOG Developer

1 Registered trials

What is Benzgalantamine?

Benzgalantamine (Zunveyl) is a delayed-release formulation of galantamine, an acetylcholinesterase inhibitor. It is being studied in Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Zunveyl, ALPHA-1062, GLN-1062
Drug type: Small molecule
Targets: acetylcholinesterase (ACHE)
Mechanism: Inhibitor of acetylcholinesterase (ACHE)
Pathways: cholinergic signaling
Therapy area: Neurology
Developer: Alpha Cognition (ACOG)
FDA status: Approved as Zunveyl (July 26, 2024), NDA218549
UNII: XOI2Q0ZF7G

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07633470	Phase 4	Alzheimer Disease	Recruiting	ACOG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer Disease

More from Alpha Cognition

211At-NaAt Phase 1 Zorifertinib Phase 2/3

Sources

ClinicalTrials.gov NCT07633470

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACOG page.

Follow ACOG, the company behind Benzgalantamine

See ACOG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACOG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z